

1 **Comparative IgG responses to SARS-CoV-2 after natural infection or vaccination**

2

3 Kaylan M. Olds, MS,¹ Devon P. Humphreys, MA,¹ Kathleen M. Gavin, PhD,^{1,2} Anne L. Wyllie,

4 PhD³ and Timothy A. Bauer, PhD^{1,2*}

5 ¹ Everly Health, Inc., 823 Congress Ave, STE 1200, Austin TX 78701

6 ² University of Colorado Anschutz Medical Campus, Aurora, CO 80045

7 ³ Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New

8 Haven, CT 06510

9 *Corresponding Author

10

11 **Address for correspondence:**

12 Timothy Bauer, PhD, Everly Health, Inc., 823 Congress Ave., Suite 1200, Austin, TX 78701;

13 phone: 303-503-5713; email: tbauer@everlyhealth.com

14

15 **Keywords:**

16 COVID-19; humans; adults; immunity; seroprevalence; antibody durability; dried blood spot

17

18

19

20 **Abstract**

21 Background: Whether vaccination or natural infection provides greater benefit regarding the
22 development of sustained immunity against SARS-CoV-2 remains unknown. Therefore, the aim
23 of this study was to provide a direct comparison of IgG durability in vaccinated and
24 unvaccinated adults.

25 Methods: This was a prospective, cross-sectional study of antibody durability in 1087 individuals
26 with a median (IQR) age of 42 (35, 52) years who were unvaccinated and previously infected
27 with SARS-CoV-2 (Arm 1, n=351) or vaccinated against the virus (Arm 2, n=737). Participants
28 self-reported vaccination and infection history and provided self-collected serology samples
29 using mailed collection kits.

30 Results: Anti-S1 IgG seroprevalence was 15.6% higher in vaccinated versus unvaccinated,
31 previously-infected individuals across intervals ranging from 1 to 12 months and antibody
32 survival was sustained near 100% through 12 months in the vaccinated group.

33 Conclusions: These findings suggest that vaccination as opposed to natural infection alone
34 provides significant advantages in terms of sustained and effective immunity against prior
35 variants of SARS-CoV-2. Future efforts to characterize SARS-CoV-2 immune responses should
36 address hybrid immunity, booster status and formulation, and protection against (sub)variants of
37 Omicron and future lineages, as well as weigh the potential impact of other immune system
38 mechanisms.

39

40

41

42

43 **Introduction**

44 Throughout the course of the Coronavirus Disease 2019 (COVID-19) pandemic, the widespread
45 adoption of vaccination has been promoted for its potential to significantly curtail health and
46 economic burdens related to the spread of SARS-CoV-2, and ultimately, key to bringing the
47 pandemic to an end (1, 2). In less than a year from the World Health Organization (WHO)
48 declaring the pandemic, following an unprecedented development effort, vaccines were available
49 to most adults in western societies. However, vaccination campaigns were met with varying
50 degrees of hesitancy in portions of the population (3-5). In the intervening months, researchers
51 documented Immunoglobulin G (IgG) seroconversion and fluctuating levels of sustained
52 immunity resulting from natural infection and/or vaccination (6-15), and established a positive
53 relationship between anti-spike antibodies and clinical protection from SARS-CoV-2 (16-18).

54
55 However, the current literature does not provide a clear difference in antibody profiles acquired
56 through vaccination and natural infection. This distinction is of renewed importance at a time
57 when nearly 60% of the United States (US) population (including 75% of US children) are
58 reported to show serological evidence of community exposure (19) and the sense of urgency
59 related to vaccination has waned. Despite a growing body of literature, availability of data
60 directly comparing antibody responses following vaccination versus natural infection is limited.
61 Prospective evaluations tend to be limited in sample size (12, 14, 20-22), have short serological
62 monitoring periods,(9, 20, 22) or analyses were completed retrospectively (23, 24). Many studies
63 utilize populations of healthcare workers who may encounter infectious agents – including
64 SARS-CoV-2 – more frequently than other members of the community, limiting generalizability
65 of results due to potential repeated exposures and subclinical infections (9, 12, 20, 25). Several

66 quality studies have evaluated the effectiveness of vaccination- and/or infection-acquired
67 immunity over time, but have lacked a serological component (24-26). Therefore, in the current
68 study, we aimed to provide a direct comparison of IgG durability in vaccinated and unvaccinated
69 individuals in a prospective US sample. This work presents the largest such comparison in a
70 prospectively-collected, population-wide sample to date.

71

72 **Methods**

73 *Ethics approval and consent to participate*

74 This protocol was approved by WCG IRB (IRB registration #20210763). All participants
75 provided written informed consent prior to enrollment in the study.

76

77 *Study design*

78 This was a prospective, cross-sectional study of antibody durability in individuals who were
79 previously infected with SARS-CoV-2 (Arm 1) or vaccinated against the virus (Arm 2). The
80 study utilized electronic questionnaires and self-collected dried blood spot (DBS) samples to
81 gather data remotely from participants within the US. Upon enrollment, participants answered
82 questions about COVID-19 diagnosis and vaccination history, symptom and treatment
83 information, and other relevant medical history such as comorbid conditions and medication use.
84 Participants received a COVID-19 Antibody Home Collection Kit (Everlywell, Inc., Austin, TX)
85 to provide samples for qualitative IgG detection. Baseline data were captured to complete the
86 primary analysis of comparative IgG durability between study arms. In addition, Arm 2
87 participants repeated questionnaires and serology tests during a follow-up period for up to 9
88 months, facilitating a secondary survival analysis of vaccine-acquired IgG.

89

90 *Participant eligibility and enrollment*

91 Participants were enrolled in the study between March and November 2021. Inclusion criteria for
92 Arm 1 included prior infection with SARS-CoV-2 (evidenced by a positive diagnostic test) and
93 unvaccinated status. Eligibility for Arm 2 required receipt of at least one dose of a SARS-CoV-2
94 vaccine. All participants were required to be age 18 years or older, reside within the continental
95 US, and have access to an email account and internet service. Exclusion criteria included known
96 conditions or ongoing treatments associated with immune impairment (e.g., chemotherapy) and
97 residents of New York state. All participants provided written informed consent prior to
98 enrollment in the study, which was approved by WCG IRB (IRB study #20210763).

99

100 *Serology Testing*

101 DBS samples were self-collected at baseline and follow-up timepoints for serology testing using
102 the Anti-SARS-CoV-2 ELISA Assay (EUROIMMUN, Germany).

103

104 *Study Endpoints*

105 The primary endpoint was the expected difference in S1-binding IgG seropositivity between Arm
106 1 (unvaccinated, naturally infected individuals) and Arm 2 (vaccinated individuals) over
107 time. The secondary endpoints included: S1-binding IgG survival percentages at 4 and 12
108 months since last exposure to a vaccine product in Arm 2.

109

110 *Statistical Analysis*

111 Multiple linear regression was used to evaluate the effect size and significance of each study arm
112 (vaccination vs natural infection) on estimated seropositivity over time (binned as the number of
113 months since last vaccine dose or infection). Estimates per study arm per time interval that
114 included fewer than 3 serology values were considered under sampled and dropped prior to
115 analysis.

116
117 Additionally, a discrete-time analysis was conducted using independent z-tests of proportions at
118 1, 3, 6, 9, and 12 months to evaluate differences in seropositivity between Arms 1 and 2. P-
119 values are reported and interpretable using a Bonferroni-adjusted value of 0.005. To further
120 evaluate S1-binding IgG durability associated with vaccination, survival analysis was performed
121 using the Kaplan-Meier method. Percent survival at 4 and 12 months is reported with 95%
122 confidence intervals. This analysis was conducted in two ways, reflecting (1) time from the most
123 recent vaccination dose (i.e., a booster dose reset the interval clock), and (2) time from the initial
124 vaccination dose.

125

126 **Results**

127 *S1-binding IgG Cross-Sectional Analysis*

128 A total of 1,087 participants enrolled in the study and completed all required baseline
129 assessments for inclusion in the analysis: 351 were assigned to Arm 1 and 737 were assigned to
130 Arm 2 at baseline. Over three quarters of participants included in the cross-sectional analysis
131 were female, and the median (IQR) age was 42 (35, 52) years. Over two thirds of vaccinated
132 participants reported no previous SARS-CoV-2 infection prior to entering the study. Baseline
133 participant characteristics are summarized in Table 1.

134

135 Table 1: Participant demographics and diagnostic test history

Characteristic	Overall N = 1088	Arm 1 N = 351	Arm 2 N = 737
Sex			
Female	831 (76%)	258 (74%)	573 (78%)
Male	255 (23%)	93 (26%)	162 (22%)
Unknown	2 (0.2%)	0 (0%)	2 (0.3%)
Age			
Median (IQR)	42 (35, 52)	43 (34, 54)	42 (35, 51)
Unknown	2 (0.2%)	0 (0%)	2 (0.3%)
COVID Diagnostic History			
Known Infection	566 (52%)	351 (100%)	215 (29%)
No Known Infection	508 (47%)	0 (0%)	508 (69%)
Unknown/NA	14 (1.3%)	0 (0%)	14 (1.9%)
Vaccine Product			
Ad26.COV2.s (Johnson & Johnson)	56 (5.1%)	0 (0%)	56 (7.6%)
BNT162b2 (Pfizer)	396 (36%)	0 (0%)	396 (54%)
mRNA-1273 (Moderna)	280 (26%)	0 (0%)	280 (38%)
NVX-CoV2373 (Novavax)	1 (<0.1%)	0 (0%)	1 (0.1%)
Not Applicable	351 (32%)	351 (100%)	0 (0%)
Unknown	4 (0.4%)	0 (0%)	4 (0.5%)

136

137

138 Nearly all Arm 2 participants entered the study fully vaccinated, defined as having received all
 139 doses in the primary series of the applicable vaccine, with only 3.7% reporting partial
 140 vaccination (or only having received one dose of a two-dose primary vaccination regimen) at
 141 baseline. No participants reported receiving a booster dose prior to enrollment. The difference in
 142 time between participants' most recent confirmed exposure (positive diagnostic test date or
 143 vaccination date for Arm 1 or 2, respectively) and baseline serology test date ranged from 1 to 15
 144 months (median) after dropping under-sampled time intervals (N=1,007).

145

146 Population-wide seropositivity remained high across time intervals. The seropositivity effect size
147 associated with vaccination was 15.6% greater than the reference arm (Arm 1), independent of
148 time since vaccination (Figure 1 and Table 2).

149

150 Table 2: Difference in seropositivity by exposure mode

Time Interval	Difference in Arm 2 (Vaccinated) versus Arm 1 (Unvaccinated/Natural Infection)	Z-score	p-value
1 month	+11.9%	-28.06	1.37×10^{-173}
3 months	+14.3%	-125.62	0.00
6 months	+15.6%	-66.93	0.00
9 months	+13.5%	-13.58	2.71×10^{-42}
12 months	+11.1%	-4.33	7.34×10^{-6}

151

152 *SI-binding IgG Longitudinal Analysis in vaccinated individuals (Arm 2)*

153 A total of 1,605 samples from 737 vaccinated individuals were available for antibody survival
154 analysis. Antibody survival (with 95% CI) ranged from 99.4% (99.0%-100%) at 4 months to
155 95.5% (91.7%-99.5%) at 12 months when measured in time since the last dose received, and
156 from 99.7% (99.3% - 100%) at 4 months to 98.4% (97.1%-99.7%) at 12 months when measured
157 from the first dose. No further loss of IgG detectability was observed beyond 12 months in either
158 analysis.

159

160 Discussion

161 This study aimed to provide the first direct comparison of IgG durability in vaccinated and
162 unvaccinated individuals in a large, prospective, population-wide US sample. Both vaccination
163 against COVID-19 and natural infection with SARS-CoV-2 are associated with seroconversion
164 in most people. However, we found IgG seropositivity was significantly higher, more consistent,

165 and declined less rapidly in vaccinated individuals than in those who were unvaccinated and
166 previously infected with the virus. This pattern was evident one-month post-exposure (the
167 earliest time interval evaluated) and persisted through 12 months post infection or most recent
168 vaccination dose. One possible explanation for the discrepancy between vaccinated and naturally
169 infected groups could be the controlled dose of target antigen provided (indirectly, in many
170 cases) through vaccination, versus the inconsistent “dose” of various viral antigens acquired
171 through natural infection. In a within-subject survival analysis, vaccine-acquired IgG antibodies
172 persisted for up to 12 months (or more) in nearly all cases. This provides within-subject support
173 for strong antibody durability out to 12 months when compared to the vaccinated group (Arm 2)
174 in the cross-sectional analysis. Collectively, these analyses suggest that IgG antibodies raised
175 through vaccination are more reliably durable than those induced by a natural SARS-CoV-2
176 infection in most individuals.

177
178 Compared to prior research, our estimated rate of seropositivity decline in the unvaccinated
179 group was steeper. Alfego et al. found seropositivity decline to be approximately -0.004% per
180 day, or approximately -0.12% per month (11), while we observed a decline of -0.93% per month.
181 This may be reflective of our smaller sample size or due to an important distinction between each
182 studies’ methods. Alfego et al. evaluated seropositivity from the time of a participant’s first
183 recorded infection (positive diagnostic test) and did not take subsequent exposure events into
184 account, whereas in the current study, we measured seropositivity from the time of the most
185 recent confirmed infection. Nevertheless, the rate of seropositivity decline in the vaccinated
186 cohort was much lower than in the unvaccinated cohort. This holds true whether we compare this
187 rate to those estimates from Alfego et al. or to our own rate estimates for Arm 1 in the present

188 study. Collectively, this suggests that S-protein antibodies raised through vaccination are more
189 reliably durable than those induced by a natural SARS-CoV-2 infection in most individuals.

190
191 While neutralizing antibody (NAb) titer is a closer surrogate for immune protection, Anti-S IgG
192 testing offers an advantage in scalability as the requisite immunoassays are less burdensome in
193 terms of time, cost, complexity, and availability than functional NAb assays. Published works
194 by Harvala et al. and Lumley et al. lend support to the clinical relevance of IgG values. The
195 former reported that detection of IgG with the Euroimmun assay highly correlated with NAb
196 titers above 1:100 in convalescent blood samples (27), while the latter observed a connection
197 between S-binding IgG and protection from reinfection with earlier variants of SARS-CoV-2 in
198 previously-infected healthcare professionals followed up to 6 months (18).

199
200 Given the correlation of IgG levels with NAb titers and that NAb concentration correlates with
201 protection against infection and severe disease (16, 17), our observations suggest that vaccine-
202 acquired immunity may also be more protective than an immune response triggered by natural
203 infection alone. Our findings support similar observations made in Congolese individuals at 2
204 months post vaccination (with Ad26.COV.2 or BBIP-CorV) compared to 2, 3, or 6 months post
205 natural infection (21). However, whether a vaccine-induced IgG response provides an advantage
206 over the longer term remains unclear. For example, in a previous evaluation of purely vaccine-
207 induced NAb activity in 62 healthcare workers, which excluded cases of prior exposures or
208 breakthrough infections, Decru et al. found significant waning of neutralization activity 10
209 months after receiving a second dose of BNT162b2 (12). If NAb follows similar patterns as anti-
210 S IgG, it may be that hybrid immunity provides the most durable NAb response. More research

211 is needed to clarify which approach produces the longest enduring neutralization capability.
212 Furthermore, the limitation remains that without more prevailing use of a common reference
213 standard it is difficult to determine what level of titer is necessary for protection, whether that
214 involves full immunity or simply protection from severe disease. In addition, the contribution of
215 other immune factors (e.g., IgA and mucosal immunity) on overall protection should not be
216 overlooked, especially considering those responses may follow different patterns than IgG after
217 vaccination or natural infection.

218
219 One problem that warrants further study is the impact of symptom severity on antibody
220 responses in previously-infected individuals who become vaccinated (hybrid immunity)
221 compared to those who remain unvaccinated, given that binding IgG and NAb responses during
222 and after severe disease are higher functioning and longer lasting than when symptoms are mild
223 (28-30). Future research may also look at the relationships between viral variants and population-
224 wide antibody profiles in vaccinated and unvaccinated cohorts, as well as how antibody
225 characteristics connect to clinical outcomes and transmissibility in each group. Moreover,
226 additional focus should be paid to hybrid immunity and the impact of repeated (or breakthrough)
227 infections and boosters, including extended follow-up (8, 20) for antibody durability and titer
228 beyond one year from each type of exposure in the general population. Flexible study designs
229 that can more easily accommodate adjustments made in response to a rapidly changing viral
230 variant landscape would help future studies maintain relevance over time as SARS-CoV-2
231 transitions from pandemic to endemic circulation.

232

233 *Limitations*

234 The data for Arm 1 are cross-sectional, therefore individual rates of seroreversion could not be
235 evaluated in direct comparison to Arm 2. Additionally, limited sample sizes at later time
236 intervals reduced statistical confidence in some time-specific point estimates of seropositivity,
237 and limited cases with confirmed hybrid immunity prevented us from evaluating those
238 individuals as a separate group. Furthermore, this study relied on self-reported infection and
239 vaccination history, and only took confirmed exposures (those that resulted in a positive
240 diagnostic test) into account. There is a high likelihood that additional exposures to SARS-CoV-
241 2 went undetected and were not reflected in the self-reported COVID-19 diagnostic data;
242 however, we expect that such events would have inflated serology values most frequently in the
243 unvaccinated group. As such, these findings give a conservative estimate of the differences
244 between vaccination and natural infection in terms of antibody response. Finally, our study
245 largely coincided with circulation of the Delta variant, and reflected immune responses triggered
246 by exposure to Alpha, Beta, or Delta variants in previously-infected individuals. The Omicron
247 (BA.1) variant was discovered as this study concluded and has exhibited greater transmissibility
248 than previous variants due to a highly mutated spike protein and consequent immune evasion and
249 increased receptor affinity (31). Subsequent sublineages (BA.1.1, BA.2, BA.3, BA.4, and BA.5)
250 have since been identified and show similar or greater transmissibility and evasion of antibodies
251 compared to the parent variant (32, 33). Furthermore, a new vaccine formulation that offers more
252 protection against Omicron has been made available as a booster dose. It is uncertain how
253 combinations of variant/subvariant exposures and primary/booster vaccine formulations may
254 affect immune responses acquired through natural infection, vaccination, or hybrid exposure in a
255 rapidly shifting landscape that continues to challenge the pace of science.
256

257 **Conclusions**

258 This study was one of the first to directly compare population-level antibody durability acquired
259 through vaccination or natural infection in a nationwide sample and supports the conclusion that
260 completing the primary series of vaccination triggers a more durable and protective antibody
261 response compared to a known single infection with early variants of SARS-CoV-2. This study
262 further supports the importance of broad vaccination campaigns over relying upon natural,
263 infection-driven herd immunity alone in the fight against SARS-CoV-2. Future work
264 investigating antibody profiles resultant to booster doses, hybrid immunity, as well as repeat and
265 variant specific infections are critical in our continued understanding of SARS-CoV-2 and
266 COVID-19.

267

268 **Abbreviations**

269 COVID-19: Coronavirus Disease 2019

270 DBS: dried blood spot

271 IgG: Immunoglobulin G

272 IQR: Interquartile range

273 NAb: Neutralizing antibody

274 US: United States

275 WHO: World Health Organization

276

277 **Declarations**

278 *Ethics approval and consent to participate*

279 This protocol was approved by WCG IRB (IRB registration #20210763). All participants
280 provided written informed consent prior to enrollment in the study.

281

282 *Consent for publication*

283 Not applicable.

284

285 *Availability of data and materials*

286 The datasets used and/or analyzed during the current study are available from the corresponding
287 author on reasonable request.

288

289 *Competing interests*

290 Kaylan Olds, Devon Humphreys, Kathleen Gavin, and Timothy Bauer are full time employees of
291 Everly Health, Inc. Anne Wylie has no conflicts to report.

292

293 *Funding*

294 This study was funded and conducted by Everly Health, Inc.

295

296 *Authors' contributions*

297 KMO: Had a role in study conception, data interpretation, and drafted the work, DPH: Had a role
298 in study conception, performed data analysis and interpretation, and assisted in drafting the work,

299 KMG: Performed data interpretation and assisted in drafting the work, ALW: Had a role in data

300 analysis, data interpretation, and assisted in drafting the work, TAB: Led study conception, data

301 interpretation, and assisted in drafting the work. All authors have reviewed and

302 approved this submitted version of the manuscript.

303

304 *Acknowledgements*

305 The authors thank PerkinElmer Genomics, Inc. for providing in-kind support with serology
306 testing.

307

308 **References**

309 1. Iboi EA, Ngonghala CN, Gumel AB. Will an imperfect vaccine curtail the COVID-19
310 pandemic in the U.S.? *Infect Dis Model.* 2020;5:510-24.

311 2. Shah SMA, Rasheed T, Rizwan K, Bilal M, Iqbal HMN, Rasool N, et al. Risk
312 management strategies and therapeutic modalities to tackle COVID-19/SARS-CoV-2. *J Infect*
313 *Public Health.* 2021;14(3):331-46.

314 3. Kreps S, Prasad S, Brownstein JS, Hswen Y, Garibaldi BT, Zhang B, et al. Factors
315 Associated With US Adults' Likelihood of Accepting COVID-19 Vaccination. *JAMA Netw*
316 *Open.* 2020;3(10):e2025594.

317 4. Ball P. Anti-vaccine movement could undermine efforts to end coronavirus pandemic,
318 researchers warn. *Nature.* 2020;581(7808):251.

319 5. Szilagyi PG, Thomas K, Shah MD, Vizueta N, Cui Y, Vangala S, et al. National Trends
320 in the US Public's Likelihood of Getting a COVID-19 Vaccine-April 1 to December 8, 2020.
321 *JAMA.* 2020.

322 6. Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman LS, Ash N, et al.
323 Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2. *N Engl J Med.*
324 2022;386(23):2201-12.

- 325 7. Amirthalingam G, Bernal JL, Andrews NJ, Whitaker H, Gower C, Stowe J, et al.
326 Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in
327 England. *Nat Commun.* 2021;12(1):7217.
- 328 8. Prendecki M, Clarke C, Brown J, Cox A, Gleeson S, Guckian M, et al. Effect of previous
329 SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine.
330 *Lancet.* 2021;397(10280):1178-81.
- 331 9. Payne RP, Longet S, Austin JA, Skelly DT, Dejnirattisai W, Adele S, et al.
332 Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. *Cell.*
333 2021;184(23):5699-714.e11.
- 334 10. McDade TW, Sancilio A, D'Aquila R, Mustanski B, Vaught LA, Reiser NL, et al. Low
335 Levels of Neutralizing Antibodies After Natural Infection With Severe Acute Respiratory
336 Syndrome Coronavirus 2 in a Community-Based Serological Study. *Open Forum Infect Dis.*
337 2022;9(3):ofac055.
- 338 11. Alfego D, Sullivan A, Poirier B, Williams J, Adcock D, Letovsky S. A population-based
339 analysis of the longevity of SARS-CoV-2 antibody seropositivity in the United States.
340 *EClinicalMedicine.* 2021;36:100902.
- 341 12. Decru B, Van Elslande J, Steels S, Van Pottelbergh G, Godderis L, Van Holm B, et al.
342 IgG Anti-Spike Antibodies and Surrogate Neutralizing Antibody Levels Decline Faster 3 to 10
343 Months After BNT162b2 Vaccination Than After SARS-CoV-2 Infection in Healthcare
344 Workers. *Front Immunol.* 2022;13:909910.
- 345 13. Yang Y, Yang M, Peng Y, Liang Y, Wei J, Xing L, et al. Longitudinal analysis of
346 antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months
347 after infection. *Nat Microbiol.* 2022;7(3):423-33.

- 348 14. Wang Z, Muecksch F, Schaefer-Babajew D, Finkin S, Viant C, Gaebler C, et al.
349 Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. *Nature*.
350 2021;595(7867):426-31.
- 351 15. Pérez-Alós L, Armenteros JJA, Madsen JR, Hansen CB, Jarlhelt I, Hamm SR, et al.
352 Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors. *Nat*
353 *Commun*. 2022;13(1):1614.
- 354 16. Addetia A, Crawford KHD, Dingens A, Zhu H, Roychoudhury P, Huang ML, et al.
355 Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a
356 Fishery Vessel Outbreak with a High Attack Rate. *J Clin Microbiol*. 2020;58(11).
- 357 17. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al.
358 Neutralizing antibody levels are highly predictive of immune protection from symptomatic
359 SARS-CoV-2 infection. *Nat Med*. 2021;27(7):1205-11.
- 360 18. Lumley SF, O'Donnell D, Stoesser NE, Matthews PC, Howarth A, Hatch SB, et al.
361 Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers. *N Engl J*
362 *Med*. 2021;384(6):533-40.
- 363 19. Clarke KEN, Jones JM, Deng Y, Nycz E, Lee A, Iachan R, et al. Seroprevalence of
364 Infection-Induced SARS-CoV-2 Antibodies - United States, September 2021-February 2022.
365 *MMWR Morb Mortal Wkly Rep*. 2022;71(17):606-8.
- 366 20. Arkell P, Gusmao C, Sheridan SL, Tanesi MY, Gomes N, Oakley T, et al. Serological
367 surveillance of healthcare workers to evaluate natural infection- and vaccine-derived immunity
368 to SARS-CoV-2 during an outbreak in Dili, Timor-Leste. *Int J Infect Dis*. 2022;119:80-6.


- 369 21. Batchi-Bouyou AL, Djontu JC, Vouvougui JC, Mfoutou Mapanguy CC, Lobaloba
370 Ingoba L, Mougany JS, et al. Assessment of neutralizing antibody responses after natural SARS-
371 CoV-2 infection and vaccination in congolese individuals. *BMC Infect Dis.* 2022;22(1):610.
- 372 22. Bonura F, Genovese D, Amodio E, Calamusa G, Sanfilippo GL, Cacioppo F, et al.
373 Neutralizing Antibodies Response against SARS-CoV-2 Variants of Concern Elicited by Prior
374 Infection or mRNA BNT162b2 Vaccination. *Vaccines (Basel).* 2022;10(6).
- 375 23. Altarawneh HN, Chemaitelly H, Ayoub HH, Tang P, Hasan MR, Yassine HM, et al.
376 Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections. *N Engl J*
377 *Med.* 2022;387(1):21-34.
- 378 24. Gazit S, Shlezinger R, Perez G, Lotan R, Peretz A, Ben-Tov A, et al. SARS-CoV-2
379 Naturally Acquired Immunity vs. Vaccine-induced Immunity, Reinfections versus Breakthrough
380 Infections: a Retrospective Cohort Study. *Clin Infect Dis.* 2022.
- 381 25. Lumley SF, Rodger G, Constantinides B, Sanderson N, Chau KK, Street TL, et al. An
382 Observational Cohort Study on the Incidence of Severe Acute Respiratory Syndrome
383 Coronavirus 2 (SARS-CoV-2) Infection and B.1.1.7 Variant Infection in Healthcare Workers by
384 Antibody and Vaccination Status. *Clin Infect Dis.* 2022;74(7):1208-19.
- 385 26. Hall V, Foulkes S, Insalata F, Kirwan P, Saei A, Atti A, et al. Protection against SARS-
386 CoV-2 after Covid-19 Vaccination and Previous Infection. *N Engl J Med.* 2022;386(13):1207-
387 20.
- 388 27. Harvala H, Robb ML, Watkins N, Ijaz S, Dicks S, Patel M, et al. Convalescent plasma
389 therapy for the treatment of patients with COVID-19: Assessment of methods available for
390 antibody detection and their correlation with neutralising antibody levels. *Transfus Med.*
391 2021;31(3):167-75.

- 392 28. Legros V, Denolly S, Vogrig M, Boson B, Siret E, Rigail J, et al. A longitudinal study of
393 SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and
394 COVID-19 severity. *Cell Mol Immunol.* 2021;18(2):318-27.
- 395 29. Rijkers G, Murk JL, Wintermans B, van Looy B, van den Berge M, Veenemans J, et al.
396 Differences in Antibody Kinetics and Functionality Between Severe and Mild Severe Acute
397 Respiratory Syndrome Coronavirus 2 Infections. *J Infect Dis.* 2020;222(8):1265-9.
- 398 30. Scheiblauer H, Nübling CM, Wolf T, Khodamoradi Y, Bellinghausen C, Sonntagbauer
399 M, et al. Antibody response to SARS-CoV-2 for more than one year - kinetics and persistence of
400 detection are predominantly determined by avidity progression and test design. *J Clin Virol.*
401 2022;146:105052.
- 402 31. McCallum M, Czudnochowski N, Rosen LE, Zepeda SK, Bowen JE, Walls AC, et al.
403 Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement. *Science.*
404 2022;375(6583):864-8.
- 405 32. Maxmen A. Why call it BA.2.12.1? A guide to the tangled Omicron family. *Nature.*
406 2022;606(7914):446-7.
- 407 33. Yao L, Zhu KL, Jiang XL, Wang XJ, Zhan BD, Gao HX, et al. Omicron subvariants
408 escape antibodies elicited by vaccination and BA.2.2 infection. *Lancet Infect Dis.*
409 2022;22(8):1116-7.
- 410
- 411
- 412
- 413
- 414

415 **Figure**

416 Figure 1. Anti-S1 seropositivity in unvaccinated/naturally infected (Arm 1) and vaccinated (Arm

417 2) groups



418